A review of cancer chemopreventive agents

被引:66
作者
Levi, MS [1 ]
Borne, RF [1 ]
Williamson, JS [1 ]
机构
[1] Univ Mississippi, Sch Pharm, Dept Med Chem, University, MS 38677 USA
关键词
D O I
10.2174/0929867013372229
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the late 20(th) century, the treatment of cancer began to include its prevention. Today, compounds exist that will lower the risk of developing certain types of cancer. This has been demonstrated in studies where chemically induced tumor growth has been slowed or reversed. Anti-inflammatory compounds having chemopreventive activity are piroxicam, sulindac, aspirin, celecoxib and curcumin. The selective estrogen receptor modulators, tamoxifen and raloxifene, are beneficial in the prevention of estrogendependent tumors. Retinoids, vitamin A derivatives, such as targretin and fenretinide are useful in the prevention of tumors. Compounds containing sulfur, such as sulforaphane and oltipraz, are even useful as radioprotective agents. The steroid dehydroepiandosterone can inhibit experimental carcinogenesis. All of these chemical classes provide a start for the medicinal chemist to design more effective chemopreventive agents. The biomarkers used to determine the chemopreventive activity of new compounds are quite often activities of enzymes. The identification of those individuals at high risk is still in its infancy and presents a troubling dilemma.
引用
收藏
页码:1349 / 1362
页数:14
相关论文
共 161 条
[61]   FARNESOL MODIFICATION OF KIRSTEN-RAS EXON 4B-PROTEIN IS ESSENTIAL FOR TRANSFORMATION [J].
JACKSON, JH ;
COCHRANE, CG ;
BOURNE, JR ;
SOLSKI, PA ;
BUSS, JE ;
DER, CJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (08) :3042-3046
[62]   Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells [J].
Jee, SH ;
Shen, SC ;
Tseng, CR ;
Chiu, HC ;
Kuo, ML .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (04) :656-661
[63]   A 2-STEP MECHANISM FOR INTERACTION OF ESTRADIOL WITH RAT UTERUS [J].
JENSEN, EV ;
SUZUKI, T ;
KAWASHIMA, T ;
STUMPF, WE ;
JUNGBLUT, PW ;
DESOMBRE, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1968, 59 (02) :632-+
[64]  
JENSEN EV, 1971, NATL CANCER I MONOGR, P55
[65]  
Jiang MC, 1996, ONCOGENE, V13, P609
[66]  
JONES DA, 1993, J BIOL CHEM, V268, P9049
[67]  
Jones EE, 1941, CANCER RES, V1, P787
[68]   THE DEVELOPMENT OF TAMOXIFEN FOR BREAST-CANCER THERAPY - A TRIBUTE TO THE LATE WALPOLE,ARTHUR L [J].
JORDAN, VC .
BREAST CANCER RESEARCH AND TREATMENT, 1988, 11 (03) :197-209
[69]  
JORDAN VC, 1989, LANCET, V1, P733
[70]  
JORDAN VC, 1994, LONG TERM TAMOXIFEN, P3